Oxygen Therapy for Pulmonary Hypertension: Guidelines, Survival Data, and Living Well

Pulmonary hypertension causes high blood pressure in the arteries of the lungs, and one of its most common consequences is low blood oxygen. Oxygen therapy is a frontline treatment for managing this complication. It will not cure the underlying disease, but it can reduce strain on the heart, improve exercise tolerance, and in some cases extend survival. Understanding when oxygen helps, how much to use, and what to expect is essential for anyone living with this condition.

Why Pulmonary Hypertension Causes Low Oxygen

In a healthy lung, blood flows through thin-walled capillaries wrapped around air sacs (alveoli). Oxygen passes easily from inhaled air into the blood. Carbon dioxide moves the other direction and gets exhaled.

Pulmonary hypertension disrupts this exchange in several ways:

• Thickened vessel walls. The small arteries in the lungs become narrowed and stiff. Less blood reaches the gas exchange surfaces.
• Right heart strain. The right ventricle has to pump harder against increased resistance. Over time, it weakens, reducing cardiac output and tissue oxygen delivery.
• Ventilation-perfusion mismatch. Some areas of the lung receive air but not enough blood flow. Other areas receive blood but not enough air. Both patterns reduce oxygen transfer.
• Hypoxic vasoconstriction. When oxygen levels drop, the lung arteries constrict further. This creates a vicious cycle: low oxygen causes more constriction, which causes lower oxygen.

The result is hypoxemia, which means the oxygen level in arterial blood falls below normal. Patients experience shortness of breath, fatigue, dizziness, and reduced exercise capacity.

How Oxygen Therapy Helps

Supplemental oxygen breaks the cycle at a critical point. By increasing the oxygen concentration in inhaled air from 21% (room air) to 24-40% or higher, it:

• Reverses hypoxic vasoconstriction. Higher alveolar oxygen levels signal the pulmonary arteries to relax, directly reducing pulmonary artery pressure.¹
• Reduces right heart workload. Lower pulmonary pressures mean the right ventricle does not have to work as hard to pump blood through the lungs.
• Improves tissue oxygenation. Organs and muscles receive more oxygen, which translates to better function and less fatigue.
• Prevents secondary complications. Chronic hypoxemia can cause polycythemia (excess red blood cell production), cognitive impairment, and worsening heart failure. Supplemental oxygen helps prevent these.

“The traditional treatment of Group 3 PH has been to optimize treatment of the underlying lung disease and give long-term oxygen therapy to those who are hypoxic.”
Sahay et al., Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension, 2023

The WHO Classification and Why It Matters for Oxygen

Pulmonary hypertension is classified into five groups by the World Health Organization (WHO). The group determines the treatment approach, and oxygen therapy plays a different role in each:

WHO Group	Cause	Role of Oxygen Therapy
Group 1 (PAH)	Pulmonary arterial hypertension	Supplemental as needed. PAH-specific drugs are primary treatment.
Group 2	Left heart disease	Treat underlying heart failure first. Oxygen if hypoxemic.
Group 3	Lung disease/hypoxia (COPD, ILD, sleep apnea)	Long-term oxygen therapy is a primary treatment. Strongest evidence base.
Group 4 (CTEPH)	Chronic blood clots in lungs	Supplemental if needed. Surgery or riociguat are primary treatments.
Group 5	Multifactorial/unclear mechanisms	Oxygen if hypoxemic. Treat underlying condition.

Group 3 PH is where oxygen therapy has the most evidence and the strongest guideline support. These patients have PH caused by chronic lung diseases like COPD, interstitial lung disease (ILD), or sleep-disordered breathing. The hypoxemia from the lung disease drives the pulmonary hypertension, so correcting the hypoxemia with oxygen directly addresses a root cause.²

When Oxygen Is Prescribed: LTOT Criteria

Long-term oxygen therapy (LTOT) is typically prescribed when a patient meets specific criteria based on arterial blood gas measurements or pulse oximetry:

• PaO2 at or below 55 mmHg (or SpO2 at or below 88%) at rest, on room air
• PaO2 56 to 59 mmHg (or SpO2 of 89%) with evidence of right heart strain (cor pulmonale), polycythemia (hematocrit above 55%), or peripheral edema³

These criteria were established by the landmark NOTT and MRC trials in the early 1980s, which demonstrated survival benefits for COPD patients with severe hypoxemia who used supplemental oxygen. The American Thoracic Society updated its clinical practice guidelines in 2020, largely reaffirming these thresholds.³

Flow Rates and Delivery Methods

The goal of supplemental oxygen is to maintain SpO2 at or above 90% (some guidelines target 92%). The flow rate needed varies by patient:

• Resting oxygen: Typically 1 to 3 liters per minute (LPM) via nasal cannula
• Exercise oxygen: Often 1 to 2 LPM higher than the resting rate, adjusted based on a 6-minute walk test with oximetry
• Nocturnal oxygen: May be the same as resting or slightly higher, since oxygen levels naturally drop during sleep

Delivery options include:

• Nasal cannula: Most common. Comfortable for long-term use at flow rates up to 6 LPM.
• Oxygen concentrator: Stationary units for home use. Portable concentrators for mobility. These extract oxygen from room air and do not need refills.
• Compressed gas cylinders: Portable but heavy. Used as backup or for short outings.
• Liquid oxygen systems: Compact and lightweight. Allow higher flow rates. Less commonly prescribed due to cost.

Nocturnal and Exercise Oxygen

Many PH patients have oxygen levels that are acceptable at rest during the day but drop during sleep or physical activity. Two specific forms of supplemental oxygen address this:

Nocturnal Oxygen

During sleep, breathing becomes shallower and less regular. For PH patients, this can lead to significant oxygen desaturation. Nocturnal oxygen therapy maintains adequate levels through the night and may prevent morning headaches, cognitive fog, and the long-term cardiovascular consequences of repeated overnight hypoxemia.

A 2020 randomized trial in the New England Journal of Medicine examined nocturnal oxygen therapy in COPD patients who did not meet standard LTOT criteria but had overnight desaturation. The trial found no significant mortality benefit, suggesting that nocturnal oxygen alone may not improve survival in patients with moderate desaturation.⁴

Exercise Oxygen

Physical activity increases oxygen demand. For PH patients, the compromised pulmonary vasculature often cannot keep up. Portable oxygen during exercise can:

• Increase walking distance and endurance
• Reduce breathlessness during daily activities
• Allow participation in pulmonary rehabilitation programs
• Improve confidence and willingness to stay active

Does Oxygen Improve Survival in Pulmonary Hypertension?

This is the question every PH patient and family member wants answered. The evidence is nuanced:

Where Oxygen Clearly Helps: Severe Hypoxemia

The NOTT trial (1980) and MRC trial (1981) established that continuous oxygen therapy improves survival in COPD patients with severe resting hypoxemia (PaO2 below 55 mmHg). The NOTT trial showed that mortality in the nocturnal-only oxygen group was 1.94 times higher than in the continuous oxygen group (P = 0.01).⁵

The MRC trial demonstrated a 5-year survival rate of 55% in the LTOT group compared to 33% in the control group (P < 0.05), with the greatest benefit seen in patients with hypercapnia (elevated CO2).⁶

A prospective study of LTOT in COPD patients also showed improvement in mean pulmonary artery pressure and prevention of PH progression.²

Where Oxygen Does Not Help: Moderate Desaturation

The LOTT trial (2016) enrolled 738 COPD patients with moderate resting or exercise-induced desaturation (SpO2 89-93%). It found no benefit in time to death or first hospitalization with supplemental oxygen compared to no oxygen. Quality of life measures were also no different between the groups.⁷

This was a pivotal finding. It means oxygen therapy is not a universal benefit for everyone with PH or COPD. The survival advantage applies specifically to patients with severe hypoxemia.

For Non-COPD Pulmonary Hypertension

Outside of COPD-related Group 3 PH, the survival data for oxygen therapy is limited. A 2024 study (SOPHA) examining LTOT in precapillary pulmonary hypertension found that it was well tolerated and significantly improved 6-minute walking distance, but larger controlled trials are needed to confirm survival benefits.⁸

“In patients with stable COPD and resting or exercise-induced moderate desaturation, long-term supplemental oxygen did not result in a longer time to death or first hospitalization.”
The LOTT Research Group, NEJM, 2016

Living with Pulmonary Hypertension and Oxygen

Using supplemental oxygen is a daily reality for many PH patients. Here are practical considerations:

• Acceptance takes time. Many patients resist oxygen because of stigma or inconvenience. Studies consistently show that patients who use their oxygen as prescribed do better than those who skip sessions.
• Stay active. Oxygen during exercise enables participation in pulmonary rehabilitation, which independently improves outcomes in PH.
• Monitor your levels. A pulse oximeter ($20-50) lets you track your SpO2 at home, during activity, and overnight. Share the data with your care team.
• Plan for travel. Airlines require advance notification and have specific rules for portable oxygen concentrators. FAA-approved devices are available.
• Manage equipment. Work with your durable medical equipment (DME) provider to ensure backup supplies, maintenance, and proper fit of your cannula.
• Address dryness. Supplemental oxygen can dry out nasal passages. A humidifier bottle attached to your concentrator helps. Water-based nasal gels also work.

When to Talk to Your Doctor

If you have pulmonary hypertension, discuss oxygen therapy with your PH specialist if:

• Your SpO2 drops below 90% at rest, during sleep, or during mild activity
• You experience increasing fatigue, shortness of breath, or swelling in your legs
• You have been prescribed oxygen but are not using it consistently
• Your current flow rate does not keep your levels above target during exercise

PH management is best handled by a specialized PH center. General practitioners and pulmonologists may not be familiar with the specific nuances of oxygen therapy in different PH groups.²

The Bottom Line

Oxygen therapy is a cornerstone treatment for pulmonary hypertension patients with low blood oxygen, particularly those in WHO Group 3. For patients with severe hypoxemia, long-term oxygen therapy can nearly double survival at 2 years. For those with moderate desaturation, the survival benefit has not been demonstrated, though quality-of-life improvements may still be meaningful.

The key is proper evaluation by a PH specialist, individualized prescribing based on your oxygen levels at rest and during activity, and consistent use of your prescribed oxygen. It is a tool, not a cure, but it remains one of the most important tools available.

1. Sahay S, Fares WH, Engelman ZJ. Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease. Pharmaceuticals. 2023;16(3):453. doi:10.3390/ph16030453
2. Nathan SD, Barbera JA, Gaine SP, et al. Group 3 pulmonary hypertension: Challenges and opportunities. Pulm Circ. 2020;10(4):2045894020950767. doi:10.1177/2045894020950767
3. Jacobs SS, Krishnan JA, Lederer DJ, et al. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(10):e121-e141. doi:10.1164/rccm.202009-3608ST
4. Lacasse Y, Series F, Corbeil F, et al. Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2020;383(12):1129-1138. doi:10.1056/NEJMoa2013219
5. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93(3):391-398. doi:10.7326/0003-4819-93-3-391
6. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981;1(8222):681-686. doi:10.1016/S0140-6736(81)91970-X
7. The Long-Term Oxygen Treatment Trial Research Group. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med. 2016;375(17):1617-1627. doi:10.1056/NEJMoa1604344
8. Waxman AB, Grunig E, et al. Long-term oxygen therapy in precapillary pulmonary hypertension – SOPHA study. Sci Rep. 2024;14:19291. doi:10.1038/s41598-024-70650-w